Clarity Strengthens Copper-64 Supply Chain for Future Commercialisation
Clarity Pharmaceuticals (ASX: CU6), a clinical-stage radiopharmaceutical company, has entered into a large-scale manufacturing supply agreement with Theragenics to secure copper-64 production in the United States. The partnership utilizes Theragenics’ advanced facility and cyclotron network to enable high-volume output, supporting Clarity’s planned commercial launch of its lead diagnostic candidate, 64Cu-SAR-bisPSMA, subject to regulatory approval.
The agreement strengthens Clarity’s existing supply network by expanding geographic reach and ensuring consistent availability of copper-64 across major oncology markets. The isotope’s longer half-life offers improved logistics and scheduling flexibility, overcoming limitations associated with shorter-lived alternatives.
With Phase III trials nearing completion and encouraging clinical progress, Clarity is advancing its commercial preparedness. The collaboration also enhances scalability and operational efficiency, aligning with the company’s strategy to broaden access to innovative radiopharmaceutical solutions for cancer diagnosis and treatment.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Clarity Strengthens Copper-64 Supply Chain for Future Commercialisation
Clarity Pharmaceuticals (ASX: CU6), a clinical-stage radiopharmaceutical company, has entered into a large-scale manufacturing supply agreement with Theragenics to secure copper-64 production in the United States. The partnership utilizes Theragenics’ advanced facility and cyclotron network to enable high-volume output, supporting Clarity’s planned commercial launch of its lead diagnostic candidate, 64Cu-SAR-bisPSMA, subject to regulatory approval.
The agreement strengthens Clarity’s existing supply network by expanding geographic reach and ensuring consistent availability of copper-64 across major oncology markets. The isotope’s longer half-life offers improved logistics and scheduling flexibility, overcoming limitations associated with shorter-lived alternatives.
With Phase III trials nearing completion and encouraging clinical progress, Clarity is advancing its commercial preparedness. The collaboration also enhances scalability and operational efficiency, aligning with the company’s strategy to broaden access to innovative radiopharmaceutical solutions for cancer diagnosis and treatment.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au